The ultimate goal of precision medicine is a unique drug for each patient. However, this N-of-1 model directly conflicts with the current economic and regulatory system, which incentivizes developing drugs for large populations to recoup massive R&D and approval costs.

After a successful trial showed GIK could halve cardiac arrest and mortality, researchers were surprised it wasn't adopted. Pharmaceutical companies refused to manufacture the simple glucose, insulin, and potassium mixture because it didn't fit their business model of patenting a new drug and marketing it heavily. This forced the researchers to form their own company.

Unlike traditional pharmaceuticals, cell therapies are patient-specific (one batch, one patient). This makes the centralized global manufacturing model inefficient. A decentralized, local production network is essential for global accessibility and scalability, fundamentally changing the supply chain strategy.

Gaining FDA approval is not the finish line. Many innovative devices fail because they lack a clear reimbursement strategy. Founders must build the economic case for payers and providers in concert with their clinical and regulatory strategy from day one.

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.

In healthcare, the user, recommender, and payer are often different entities. A clinically effective product can easily fail if it's not inserted into the right point in the value chain where a stakeholder is both willing and incentivized to pay for it.

The biotech industry often oversimplifies the challenge of genetic medicine as a 'delivery' problem. In reality, it's three distinct but interconnected issues—potency, specificity, and delivery—masquerading as one. Solving it requires a complex, multi-faceted solution, not a single silver bullet, which is why progress has been slow.

A common strategic error in biotech is assuming a therapeutic delivery system that works for one part of the body (e.g., the liver) constitutes a universal 'platform.' In reality, effective platforms must be built organ-by-organ; a system for targeting tumors is fundamentally different from one for T-cells or kidneys.

The industry mantra "the process is the product" is misleading. While process engineering is crucial, its value is entirely dependent on the clinical success of the biopharmaceutical. Without an effective drug, even the most sophisticated, AI-driven manufacturing process has no use case.